MedPath

A study to compare effectiveness for preventing disease recurrence and safety regarding drug related side effects between one month vs. two month of alternate day oral steroid in children with nephrotic syndrome, a chronic protein losing kidney disease.

Phase 3
Recruiting
Conditions
Nephrotic Syndrome
Registration Number
CTRI/2015/01/005363
Lead Sponsor
NRS Medical College and Hospital
Brief Summary

The vast majority of children with idiopathic nephrotic syndromerespond well to corticosteroid treatment. However, as many as 80% experience  a relapse. Repeated and prolongedcourses of steroids in these children often result in long-term complications.The goal of treatment is to reduce the rate of relapses, the cumulative dose ofcorticosteroids, and the incidence of serious complications. In order tominimize the side effects of steroid therapy, different steroid doses andschedules are used. Standard therapy of 1 month alternate day steroid for managingrelapse results in further relapse  among50% of children. Various recent reports are suggesting that prolongation ofthis alternate day steroid keeping the cumulative steroid load same, mayproduce better efficacy in preventing further relapses.1-5 Studiescomparing the usefulness of these two schedules are lacking. In our proposed randomized controlled trial, we wantto compare the efficacy and safety of one month vs. two month of alternate dayoral steroid in managing relapse of Idiopathic Steroid Sensitive NephroticSyndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
120
Inclusion Criteria

Infrequent relapse nephrotic syndrome; No previously intake of any steroid sparing agent; Informed written consent.

Exclusion Criteria

Patients with severe leucopenia (leucocytes <3•0× 1000 cells/mm3), severe anemia (haemoglobin <8•9 g/dl), severe thrombocytopenia (platelet <100•0 × 1000 cells/mm3), deranged liver function tests (AST or ALT to >50 IU/L), or any active infection.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sustained remission at 12 months3,6,9 and 12 month
Secondary Outcome Measures
NameTimeMethod
number of relapses, cumulative steroid dose3,6,9 and 12 month

Trial Locations

Locations (1)

Room No.16, Div. of Pediatric Nephrology and OPD, Dept. of Pediatrics, NRS Medical College

🇮🇳

Kolkata, WEST BENGAL, India

Room No.16, Div. of Pediatric Nephrology and OPD, Dept. of Pediatrics, NRS Medical College
🇮🇳Kolkata, WEST BENGAL, India
Biswanath Basu
Principal investigator
basuv3000@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.